90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

NCT05139004 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

7

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Secondary Acute Myeloid Leukemia

Interventions

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation
BIOLOGICAL: Basiliximab
DRUG: Fludarabine Phosphate
DRUG: Indium In 111-DOTA-Basiliximab
DRUG: Melphalan
BIOLOGICAL: Palifermin
RADIATION: Total Lymphoid Irradiation
RADIATION: Total Marrow Irradiation
BIOLOGICAL: Yttrium Y 90 Basiliximab

Sponsor

City of Hope Medical Center

Collaborators

[object Object]